Celprogen Introduces an in vivo Model for Human Brain Cancer for Drug Discovery Applications
News Nov 19, 2008
Celprogen Inc. has announced that they have successfully validated an in vivo model system for testing efficacy of cancer drugs and also novel drug candidates for Human Glioblastoma. This in vivo model system has been validated within United States research facilities for testing novel drug candidates against Human Glioblastoma.
Celprogen’s in vivo model system would enable scientists all over the world to test their potential drug candidates against Human Brain Cancer (GBM), which is one of the hardest human cancers to treat and diagnose.
Celprogen has established a Drug Discovery program to provide drug efficacy testing services to major Pharmaceutical firms for their potential drugs against Human Glioblastoma.
The other in vivo cancer model systems in the pipe line at Celprogen are: breast cancer, prostate cancer, liver cancer, colon cancer, lung cancer and pancreatic cancer that are scheduled to be released as early as the beginning of second quarter 2009. These in vivo cancer model systems are being generated from already established Celprogen’s Cancer Stem Cells.